Last reviewed · How we verify
Extended bolus of insulin then standard bolus of insulin
Extended bolus of insulin then standard bolus of insulin is a Small molecule drug developed by University of California, San Francisco. It is currently FDA-approved.
At a glance
| Generic name | Extended bolus of insulin then standard bolus of insulin |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended bolus of insulin then standard bolus of insulin CI brief — competitive landscape report
- Extended bolus of insulin then standard bolus of insulin updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Extended bolus of insulin then standard bolus of insulin
What is Extended bolus of insulin then standard bolus of insulin?
Extended bolus of insulin then standard bolus of insulin is a Small molecule drug developed by University of California, San Francisco.
Who makes Extended bolus of insulin then standard bolus of insulin?
Extended bolus of insulin then standard bolus of insulin is developed and marketed by University of California, San Francisco (see full University of California, San Francisco pipeline at /company/university-of-california-san-francisco).
What development phase is Extended bolus of insulin then standard bolus of insulin in?
Extended bolus of insulin then standard bolus of insulin is FDA-approved (marketed).